Immuno-oncology
Conference Coverage
PACIFIC: Durvalumab extends PFS in stage 3 NSCLC
From the Journals
Pembrolizumab, nivolumab linked to 3% rate of neurologic events
Ten of 347 patients (2.9%) receiving nivolumab or pembrolizumab developed subacute neurologic immune-related adverse events, typically...
News
FDA approves first gene therapy – tisagenlecleucel for ALL
“New technologies such as gene and cell therapies hold out the potential to transform medicine and create an inflection point in our ability to...
From the Journals
Adverse effects of PD-1/PD-L1 inhibitors varied by tumor type in systematic review
Patients with melanoma who received PD-1/PD-L1 inhibitors were significantly more likely to develop colitis, diarrhea, pruritus, and rash,...
News
FDA approves nivolumab for metastatic CRC
The indication includes patients aged 12 years and older with mismatch repair deficient and microsatellite instability high metastatic colorectal...
News
Enasidenib gets FDA approval for AML with IDH2 mutations
“Idhifa is a targeted therapy that fills an unmet need for patients with relapsed or refractory AML who have an IDH2 mutation,” said Richard...
Feature
New SU2C translational team aims to apply CAR T-cell therapy to pancreatic cancer
Can CAR T-cell therapy make a difference in hard-to-treat pancreatic cancer?
Conference Coverage
Pembrolizumab takes on r/r PMBCL
LUGANO, SWITZERLAND – Keynote 170 investigators are enrolling adults with relapsed/refractory PMBCL who are either ineligible for ASCT following...
Conference Coverage
Avelumab induces response in Hodgkin lymphoma after failed allo-SCT
LUGANO, SWITZERLAND – The immune checkpoint inhibitor avelumab showed efficacy against classical Hodgkin lymphoma among patients with disease...
Latest News
IMiD/Anti-CD20 combo induces complete responses in r/r NHL
Lugano, Switzerland – A combination of obinutuzumab (Gazyva) and the experimental immunomodulatory agent CC-122 showed “clinically meaningful”...
News
All FDA panel members go thumbs up for CTL019 in relapsed/refractory childhood ALL
Steps need to be taken to mitigate the risk of cytokine release syndrome and neurologic events and the potential for secondary malignancies.